- Home
- BDRX vs SONN Comparison
BDRX vs SONN Comparison
Compare BDRX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- SONN
- Stock Information
- Founded
- BDRX 2000
- SONN N/A
- Country
- BDRX United Kingdom
- SONN United States
- Employees
- BDRX N/A
- SONN N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- SONN Health Care
- Exchange
- BDRX Nasdaq
- SONN Nasdaq
- Market Cap
- BDRX 2.4M
- SONN 2.5M
- IPO Year
- BDRX N/A
- SONN N/A
- Fundamental
- Price
- BDRX $1.33
- SONN $1.31
- Analyst Decision
- BDRX
- SONN Strong Buy
- Analyst Count
- BDRX 0
- SONN 2
- Target Price
- BDRX N/A
- SONN $38.00
- AVG Volume (30 Days)
- BDRX 3.5M
- SONN 37.4K
- Earning Date
- BDRX 04-21-2025
- SONN 05-13-2025
- Dividend Yield
- BDRX N/A
- SONN N/A
- EPS Growth
- BDRX N/A
- SONN N/A
- EPS
- BDRX N/A
- SONN N/A
- Revenue
- BDRX $104,895.00
- SONN $1,000,000.00
- Revenue This Year
- BDRX N/A
- SONN N/A
- Revenue Next Year
- BDRX N/A
- SONN N/A
- P/E Ratio
- BDRX N/A
- SONN N/A
- Revenue Growth
- BDRX N/A
- SONN 674.14
- 52 Week Low
- BDRX $1.14
- SONN $1.22
- 52 Week High
- BDRX $74.00
- SONN $16.80
- Technical
- Relative Strength Index (RSI)
- BDRX 35.57
- SONN 39.74
- Support Level
- BDRX $1.14
- SONN $1.33
- Resistance Level
- BDRX $2.65
- SONN $1.35
- Average True Range (ATR)
- BDRX 0.24
- SONN 0.09
- MACD
- BDRX 0.01
- SONN -0.00
- Stochastic Oscillator
- BDRX 26.49
- SONN 36.00
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.